213 related articles for article (PubMed ID: 27450784)
1. Relationship of paraoxonase-1 Q192R genotypes and in-stent restenosis and re-stenting in Chinese patients after coronary stenting.
Ma W; Liang Y; Zhu J; Chen T; Feng G; Yang Y; Liu X; Wang X
Atherosclerosis; 2016 Aug; 251():305-310. PubMed ID: 27450784
[TBL] [Abstract][Full Text] [Related]
2. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A
Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
[TBL] [Abstract][Full Text] [Related]
3. Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention.
Tang XF; Wang J; Zhang JH; Meng XM; Xu B; Qiao SB; Wu YJ; Chen J; Wu Y; Chen JL; Gao RL; Yuan JQ; Yang YJ
Eur J Clin Pharmacol; 2013 May; 69(5):1103-12. PubMed ID: 23150151
[TBL] [Abstract][Full Text] [Related]
4. PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity.
Li X; Zhang L; Chen X; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Xu Q; Zhang Y; Li Y; Lu C; Yin T
Thromb Res; 2013 Oct; 132(4):444-9. PubMed ID: 23993903
[TBL] [Abstract][Full Text] [Related]
5. [Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
Cano P; Consuegra-Sánchez L; Conesa P; Torres-Moreno D; Jaulent L; Dau D; Picó F; Villegas M
Med Clin (Barc); 2014 Jul; 143(1):6-12. PubMed ID: 23850044
[TBL] [Abstract][Full Text] [Related]
6. Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement.
Trenk D; Hochholzer W; Fromm MF; Zolk O; Valina CM; Stratz C; Neumann FJ
Circ Cardiovasc Genet; 2011 Aug; 4(4):429-36. PubMed ID: 21685174
[TBL] [Abstract][Full Text] [Related]
7. The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease.
Xie C; Ding X; Gao J; Wang H; Hang Y; Zhang H; Zhang J; Jiang B; Miao L
Pharmacogenet Genomics; 2014 Apr; 24(4):204-10. PubMed ID: 24535487
[TBL] [Abstract][Full Text] [Related]
8. The impact of cytochrome P450 2C19 polymorphism on the occurrence of one-year in-stent restenosis in patients who underwent percutaneous coronary intervention: A case-match study.
Nozari Y; Vosooghi S; Boroumand M; Poorhosseini H; Nematipour E; Salarifar M; Kassaian SE; Amirzadegan A; Alidoosti M; Haji-Zeinali AM; Saroukhani S
Anatol J Cardiol; 2015 May; 15(5):348-53. PubMed ID: 25993709
[TBL] [Abstract][Full Text] [Related]
9. Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.
Tresukosol D; Suktitipat B; Hunnangkul S; Kamkaew R; Poldee S; Tassaneetrithep B; Likidlilid A
PLoS One; 2014; 9(10):e110188. PubMed ID: 25329996
[TBL] [Abstract][Full Text] [Related]
10. The effects of polymorphisms in CYP2C19, ATP-binding cassette transporter B1, and paraoxonase-1 on clopidogrel treatment of Uygur patients following percutaneous coronary intervention.
Wang T; Li H; Wang F; Sun L; Yu L
Eur J Clin Pharmacol; 2021 Nov; 77(11):1679-1686. PubMed ID: 34164723
[TBL] [Abstract][Full Text] [Related]
11. Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome.
Peng W; Shi X; Xu X; Lin Y
Cardiovasc Ther; 2019; 2019():3470145. PubMed ID: 31772608
[TBL] [Abstract][Full Text] [Related]
12. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.
Hulot JS; Collet JP; Cayla G; Silvain J; Allanic F; Bellemain-Appaix A; Scott SA; Montalescot G
Circ Cardiovasc Interv; 2011 Oct; 4(5):422-8. PubMed ID: 21972404
[TBL] [Abstract][Full Text] [Related]
13. Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention.
Rideg O; Komócsi A; Magyarlaki T; Tokés-Füzesi M; Miseta A; Kovács GL; Aradi D
Pharmacogenomics; 2011 Sep; 12(9):1269-80. PubMed ID: 21806387
[TBL] [Abstract][Full Text] [Related]
14. Paraoxonase-1 is not a major determinant of stent thrombosis in a Taiwanese population.
Chen DY; Wang CY; Wen MS; Lee TH; Chu Y; Hsieh MJ; Chang SH; Lee CH; Wang JL; Chen CC; Lu LS; Lee MT; Yeh SJ; Lin FC; Hsieh IC
PLoS One; 2012; 7(6):e39178. PubMed ID: 22723959
[TBL] [Abstract][Full Text] [Related]
15. [Clopidogrel metabolism related gene polymorphisms in Chinese patients with acute coronary syndrome].
Feng GX; Liang Y; Bai Y; Chen T; Liu X; Yang YM; Wang XY; Yang YJ; Zhu J
Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Nov; 40(11):908-13. PubMed ID: 23363670
[TBL] [Abstract][Full Text] [Related]
16. Paraoxonase 1 gene polymorphism does not affect clopidogrel response variability but is associated with clinical outcome after PCI.
Park KW; Park JJ; Kang J; Jeon KH; Kang SH; Han JK; Lee SE; Yang HM; Lee HY; Kang HJ; Koo BK; Oh BH; Park YB; Kim HS
PLoS One; 2013; 8(2):e52779. PubMed ID: 23418418
[TBL] [Abstract][Full Text] [Related]
17. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting.
Bouman HJ; Harmsze AM; van Werkum JW; Breet NJ; Bergmeijer TO; Ten Cate H; Hackeng CM; Deneer VH; Ten Berg JM
Heart; 2011 Aug; 97(15):1239-44. PubMed ID: 21628721
[TBL] [Abstract][Full Text] [Related]
18. Paraoxonase-1 Q192R polymorphism is not associated with clopidogrel response in Chinese stroke patients.
Yang J; Zhou JS; Tan J; He BS; Zou JJ
Pharmazie; 2012 Dec; 67(12):1026-9. PubMed ID: 23346768
[TBL] [Abstract][Full Text] [Related]
19. Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients.
Marchini JF; Pinto MR; Novaes GC; Badran AV; Pavão RB; Figueiredo GL; Lago IM; Lima-Filho MO; Lemos DC; Tonani M; Antloga CM; Oliveira L; Lorenzi JC; Marin-Neto JA
Braz J Med Biol Res; 2017 Jan; 50(1):e5660. PubMed ID: 28076455
[TBL] [Abstract][Full Text] [Related]
20. Paraoxonase-1 activity affects the clopidogrel response in CYP2C19 loss-of-function carriers.
Nishio R; Shinke T; Otake H; Nakagawa M; Inoue T; Hariki H; Osue T; Taniguchi Y; Iwasaki M; Hiranuma N; Konishi A; Kinutani H; Kuroda M; Hirata K
Thromb Res; 2013 Nov; 132(5):558-64. PubMed ID: 24080149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
